Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional studyKi67 has potential clinical importance in breast cancer but has yet to see broad acceptance due to inter-laboratory variability. Here we ...
Ki-67 assessment in breast cancer has failed to impose itself as an accepted proliferative biomarker due to its lack of reproduci- bility and the difficulty finding an appropriate cutoff (ie, 10%, 14% and 20%).9,22,26–29 Indeed, neither the American Society of Clinical Oncology nor the...
This study investigated the feasibility of predicting the expression levels of Ki-67 in breast cancer using ultrasonographic findings and clinical features. Fifty-eight breast cancer patients, with 82 lesions confirmed by surgical pathology, were selected retrospectively for this study. Conventional ultrasou...
Accurate determination of the predictive markers human epidermal growth factor receptor 2 (HER2/ERBB2), estrogen receptor (ER/ESR1), progesterone receptor (PgR/PGR), and marker of proliferation Ki67 (MKI67) is indispensable for therapeutic decision making in early breast cancer. In this multicenter...
INTRODUCTION: Breast cancer (BC) is a malignancy with very high incidence and mortality in Africa, especially in Western Africa where more than 25 thousand deaths are registered every year. Not all BC have the same prognosis, and being able to personaliz
The United States Food and Drug Administration recently approved a Ki-67 immunohistochemistry (IHC) assay to identify patients with early breast cancer at high disease recurrence risk. The Oncotype Dx Breast Recurrence Score® assay has been validated in hormone receptor-positive (HR+), human epide...
The United States Food and Drug Administration recently approved a Ki-67 immunohistochemistry (IHC) assay to identify patients with early breast cancer at high disease recurrence risk. The Oncotype Dx Breast Recurrence Score® assay has been validated in hormone receptor-positive (HR+), human epide...
Table 3 Summary of statistical analysis for 200 and 1000 cancer cells after evaluation for Ki-67 proliferation Full size table Ki67 assessment of 1000 cancer cells Analysis of 1000 cancer cells evaluated for Ki67 proliferation showed core biopsies having an absolute mean proliferation value 2.2% highe...
Effect of Ki-67 Expression Levels and Histological Grade on Breast Cancer Early Relapse in Patients with Different Immunohistochemical-based Subtypes Article Open access 06 May 2020 Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by Immunohistochemistry Article...
Ki-67 scores were recorded as the percentage of positively staining cancer cells using the MIB1 antibody, in five representative high-power fields (Zabaglo et al, 2010). The IHC4+C score was calculated using the addition of two algorithms: (i) The IHC4 score using an adjustment for Ki67...